Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to.

Published byMarika Szilágyiné Modified over 5 years ago

Similar presentations

Presentation on theme: "Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to."— Presentation transcript:

1 Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to 159/90 to 99 mmHg; stage 2, 160 to 179/100 to 109 mmHg; stage 3, ≥180/110 mmHg) (20). Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to 159/90 to 99 mmHg; stage 2, 160 to 179/100 to 109 mmHg; stage 3, ≥180/110 mmHg) (20). David A. Calhoun CJASN 2006;1: ©2006 by American Society of Nephrology

Download ppt "Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to."

Similar presentations

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Community Teaching Project: Hypertension Presented by: Mariel Alvarez, Michelle Vickers, Andy Nguyen, Lalita Poon, Minh Luong.

Community Teaching Project: Hypertension Presented by: Mariel Alvarez, Michelle Vickers, Andy Nguyen, Lalita Poon, Minh Luong.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
G protein β3 subunit C825T polymorphism in primary IgA nephropathy

G protein β3 subunit C825T polymorphism in primary IgA nephropathy
Francesco Paolo Schena  Kidney International 

Francesco Paolo Schena  Kidney International 
Patterns of mortal risk among eKt/V quintiles in the HEMO study for (A) 1 yr of follow-up and (B) after 1 yr. Patterns of mortal risk among eKt/V quintiles.

Patterns of mortal risk among eKt/V quintiles in the HEMO study for (A) 1 yr of follow-up and (B) after 1 yr. Patterns of mortal risk among eKt/V quintiles.
(A) Comparison of V, however estimated, to itself and to a transformation of V, Vt = 3.27 × V2/3 (see reference 42). (A) Comparison of V, however estimated,

(A) Comparison of V, however estimated, to itself and to a transformation of V, Vt = 3.27 × V2/3 (see reference 42). (A) Comparison of V, however estimated,
Differing renal outcomes associated with AKI electronic alerts for clinical location of AKI subsets. Differing renal outcomes associated with AKI electronic.

Differing renal outcomes associated with AKI electronic alerts for clinical location of AKI subsets. Differing renal outcomes associated with AKI electronic.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Lynda Anne Szczech, Ira L. Lazar  Kidney International 

Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.
Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Similar presentations

Ads by Google